MSB 3.77% $1.52 mesoblast limited

MSB shareholder class action, page-41

  1. 3,988 Posts.
    lightbulb Created with Sketch. 1376
    Good luck with PNV.

    The Japanese market is only a indication of the US market for Remestemcel L. US much larger and cost will be around 2 fold. It's not hard to see US$ 100 million on approval. PNV very good but has only just turned green. Market cap of 1.6 billion, this first milestone for MSB would represent a 5 fold increase in market cap.
    What you miss is the power of the market as perception of a " off the shelf stem cell product" We see many drugs that have no more than a perception of been approvalable by the regulaters valued in the multi billions. MAB drugs worth 6 - 10 billion for results that could only be described as marginal. CSL's latest fail, MC retreat of around 8 billion based on not much more than hope that they had something for MACE.
    Many drugs have these valuations. So MSB's MC is beyond imagination and has to many variables that it is impossible to predict.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.52
Change
0.055(3.77%)
Mkt cap ! $1.729B
Open High Low Value Volume
$1.48 $1.54 $1.45 $6.072M 4.049M

Buyers (Bids)

No. Vol. Price($)
1 5951 $1.52
 

Sellers (Offers)

Price($) Vol. No.
$1.52 133644 5
View Market Depth
Last trade - 16.10pm 12/11/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.